Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy?

Aus dem Siepen F, Hein S, Prestel S, Baumgärtner C, Schönland S, Hegenbart U, Röcken C, Katus HA, Kristen AV.

Clin Res Cardiol. 2019 Apr 5. doi: 10.1007/s00392-019-01467-1. [Epub ahead of print]

PMID:
30953182
2.

Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu CR, Ong ML, Coelho T, Rapezzi C; THAOS Investigators.

Eur Heart J. 2019 Apr 1. pii: ehz173. doi: 10.1093/eurheartj/ehz173. [Epub ahead of print]

PMID:
30938420
3.

Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.

Minamisawa M, Claggett B, Adams D, Kristen AV, Merlini G, Slama MS, Dispenzieri A, Shah AM, Falk RH, Karsten V, Sweetser MT, Chen J, Riese R, Vest J, Solomon SD.

JAMA Cardiol. 2019 May 1;4(5):466-472. doi: 10.1001/jamacardio.2019.0849.

4.

Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

Dittrich T, Benner A, Kimmich C, Siepen FAD, Veelken K, Kristen AV, Bochtler T, Katus HA, Müller-Tidow C, Hegenbart U, Schönland SO.

Haematologica. 2019 Jul;104(7):1451-1459. doi: 10.3324/haematol.2018.205336. Epub 2019 Jan 17.

5.

Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.

Kristen AV, Ajroud-Driss S, Conceição I, Gorevic P, Kyriakides T, Obici L.

Neurodegener Dis Manag. 2019 Feb;9(1):5-23. doi: 10.2217/nmt-2018-0033. Epub 2018 Nov 27.

6.

Peak V'O2 is an independent predictor of survival in patients with cardiac amyloidosis.

Hein S, Aus Dem Siepen F, Bauer R, Katus HA, Kristen AV.

Amyloid. 2018 Sep;25(3):167-173. doi: 10.1080/13506129.2018.1496077. Epub 2018 Sep 7.

PMID:
30193539
7.

Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators.

N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.

8.

[What gnaws at the heart and gets on the nerves].

Kristen AV.

Internist (Berl). 2018 Nov;59(11):1208-1213. doi: 10.1007/s00108-018-0470-x. German.

PMID:
30039176
9.

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB.

N Engl J Med. 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153.

10.

Improved outcomes after heart transplantation for cardiac amyloidosis in the modern era.

Kristen AV, Kreusser MM, Blum P, Schönland SO, Frankenstein L, Dösch AO, Knop B, Helmschrott M, Schmack B, Ruhparwar A, Hegenbart U, Katus HA, Raake PWJ.

J Heart Lung Transplant. 2018 May;37(5):611-618. doi: 10.1016/j.healun.2017.11.015. Epub 2017 Nov 15.

PMID:
29217108
11.

Predictors of survival stratification in patients with wild-type cardiac amyloidosis.

Siepen FAD, Bauer R, Voss A, Hein S, Aurich M, Riffel J, Mereles D, Röcken C, Buss SJ, Katus HA, Kristen AV.

Clin Res Cardiol. 2018 Feb;107(2):158-169. doi: 10.1007/s00392-017-1167-1. Epub 2017 Sep 27.

PMID:
28956153
12.

Sural nerve injury in familial amyloid polyneuropathy: MR neurography vs clinicopathologic tools.

Kollmer J, Sahm F, Hegenbart U, Purrucker JC, Kimmich C, Schönland SO, Hund E, Heiland S, Hayes JM, Kristen AV, Röcken C, Pham M, Bendszus M, Weiler M.

Neurology. 2017 Aug 1;89(5):475-484. doi: 10.1212/WNL.0000000000004178. Epub 2017 Jul 5.

PMID:
28679600
13.

Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.

Hegenbart U, Bochtler T, Benner A, Becker N, Kimmich C, Kristen AV, Beimler J, Hund E, Zorn M, Freiberger A, Gawlik M, Goldschmidt H, Hose D, Jauch A, Ho AD, Schönland SO.

Haematologica. 2017 Aug;102(8):1424-1431. doi: 10.3324/haematol.2016.163246. Epub 2017 May 18.

14.

Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?

Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV.

Amyloid. 2017 Mar;24(sup1):132-133. doi: 10.1080/13506129.2016.1272453. No abstract available.

PMID:
28434295
15.

Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis - Report from the Transthyretin Amyloidosis Outcome Survey (THAOS).

Kristen AV, Maurer MS, Rapezzi C, Mundayat R, Suhr OB, Damy T; THAOS investigators.

PLoS One. 2017 Apr 6;12(4):e0173086. doi: 10.1371/journal.pone.0173086. eCollection 2017.

16.

Myocardial contraction fraction derived from cardiovascular magnetic resonance cine images-reference values and performance in patients with heart failure and left ventricular hypertrophy.

Arenja N, Fritz T, Andre F, Riffel JH, Aus dem Siepen F, Ochs M, Paffhausen J, Hegenbart U, Schönland S, Müller-Hennessen M, Giannitsis E, Kristen AV, Katus HA, Friedrich MG, Buss SJ.

Eur Heart J Cardiovasc Imaging. 2017 Dec 1;18(12):1414-1422. doi: 10.1093/ehjci/jew324.

PMID:
28165128
17.

Anterior Aortic Plane Systolic Excursion: A Novel Indicator of Transplant-Free Survival in Systemic Light-Chain Amyloidosis.

Ochs MM, Riffel J, Kristen AV, Hegenbart U, Schönland S, Hardt SE, Katus HA, Mereles D, Buss SJ.

J Am Soc Echocardiogr. 2016 Dec;29(12):1188-1196. doi: 10.1016/j.echo.2016.09.003. Epub 2016 Oct 27.

PMID:
28042785
18.

Reply: Should Histologic Determination of Amyloid Load Determine Management Decisions in Light-Chain Amyloidosis?

Kristen AV, Brokbals E, Aus dem Siepen F, Bauer R, Hein S, Aurich M, Riffel J, Behrens HM, Krüger S, Schirmacher P, Katus HA, Röcken C.

J Am Coll Cardiol. 2016 Dec 6;68(22):2494-2495. doi: 10.1016/j.jacc.2016.08.068. No abstract available.

19.

Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).

Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C; THAOS Investigators.

J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. doi: 10.1016/j.jacc.2016.03.596.

20.

Cardiac Amyloid Load: A Prognostic and Predictive Biomarker in Patients With Light-Chain Amyloidosis.

Kristen AV, Brokbals E, Aus dem Siepen F, Bauer R, Hein S, Aurich M, Riffel J, Behrens HM, Krüger S, Schirmacher P, Katus HA, Röcken C.

J Am Coll Cardiol. 2016 Jul 5;68(1):13-24. doi: 10.1016/j.jacc.2016.04.035.

21.

Coronary angiography-related myocardial injury as detected by high-sensitivity cardiac troponin T assay.

Abu Sharar H, Wohlleben D, Vafaie M, Kristen AV, Volz HC, Bekeredjian R, Katus HA, Giannitsis E.

EuroIntervention. 2016 Jun 20;12(3):337-44. doi: 10.4244/EIJV12I3A54.

22.

Right ventricular long axis strain-validation of a novel parameter in non-ischemic dilated cardiomyopathy using standard cardiac magnetic resonance imaging.

Arenja N, Riffel JH, Djiokou CN, Andre F, Fritz T, Halder M, Zelniker T, Kristen AV, Korosoglou G, Katus HA, Buss SJ.

Eur J Radiol. 2016 Jul;85(7):1322-8. doi: 10.1016/j.ejrad.2016.04.017. Epub 2016 May 6.

PMID:
27235880
23.

Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy.

Damy T, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Karayal ON, Mundayat R, Suhr OB, Kristen AV.

Open Heart. 2016 Feb 8;3(1):e000289. doi: 10.1136/openhrt-2015-000289. eCollection 2016.

24.

Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study.

aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV.

Drug Des Devel Ther. 2015 Dec 4;9:6319-25. doi: 10.2147/DDDT.S96893. eCollection 2015.

25.

Fast assessment of long axis strain with standard cardiovascular magnetic resonance: a validation study of a novel parameter with reference values.

Riffel JH, Andre F, Maertens M, Rost F, Keller MG, Giusca S, Seitz S, Kristen AV, Müller M, Giannitsis E, Korosoglou G, Katus HA, Buss SJ.

J Cardiovasc Magn Reson. 2015 Aug 8;17:69. doi: 10.1186/s12968-015-0171-8.

26.

Comparison of different types of cardiac amyloidosis by cardiac magnetic resonance imaging.

Kristen AV, aus dem Siepen F, Scherer K, Kammerer R, Andre F, Buss SJ, Bauer R, Lehrke S, Voss A, Giannitsis E, Katus HA, Steen H.

Amyloid. 2015;22(2):132-41. doi: 10.3109/13506129.2015.1020153. Epub 2015 Jun 8.

PMID:
26053103
27.

Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study.

aus dem Siepen F, Buss SJ, Andre F, Seitz S, Giannitsis E, Steen H, Katus HA, Kristen AV.

Clin Res Cardiol. 2015 Aug;104(8):640-7. doi: 10.1007/s00392-015-0826-3. Epub 2015 Feb 18.

PMID:
25855392
28.

Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.

Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J.

J Cardiovasc Transl Res. 2015 Mar;8(2):117-27. doi: 10.1007/s12265-015-9613-9. Epub 2015 Mar 6.

29.

In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography.

Kollmer J, Hund E, Hornung B, Hegenbart U, Schönland SO, Kimmich C, Kristen AV, Purrucker J, Röcken C, Heiland S, Bendszus M, Pham M.

Brain. 2015 Mar;138(Pt 3):549-62. doi: 10.1093/brain/awu344. Epub 2014 Dec 18.

30.

Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis.

Riffel JH, Mereles D, Emami M, Korosoglou G, Kristen AV, Aurich M, Voss A, Schonland SO, Hegenbart U, Hardt SE, Katus HA, Buss SJ.

Amyloid. 2015 Mar;22(1):45-53. doi: 10.3109/13506129.2014.992515. Epub 2014 Dec 10.

PMID:
25492308
31.

Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.

Kristen AV, Rinn J, Hegenbart U, Lindenmaier D, Merkle C, Röcken C, Hardt S, Giannitsis E, Katus HA.

Clin Res Cardiol. 2015 Mar;104(3):250-7. doi: 10.1007/s00392-014-0779-y. Epub 2014 Oct 21.

PMID:
25331161
32.

The "Wagshurst study": p.Val40Ile transthyretin gene variant causes late-onset cardiomyopathy.

Bauer R, Dikow N, Brauer A, Kreuter M, Buss S, Evers C, Röcken C, Schnabel PA, Hinderhofer K, Ehlermann P, Katus HA, Kristen AV.

Amyloid. 2014 Dec;21(4):267-75. doi: 10.3109/13506129.2014.967846. Epub 2014 Oct 7.

PMID:
25291558
33.

Evaluation of the clinical use of midregional pro-atrial natriuretic peptide (MR-proANP) in comparison to N-terminal pro-B-type natriuretic peptide (NT-proBNP) for risk stratification in patients with light-chain amyloidosis.

Kristen AV, Biener M, Hegenbart U, Hardt S, Schnabel PA, Röcken C, Schonland SO, Katus HA, Giannitsis E.

Int J Cardiol. 2014 Oct 20;176(3):1113-5. doi: 10.1016/j.ijcard.2014.07.106. Epub 2014 Aug 1. No abstract available.

PMID:
25115253
34.

Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.

Kristen AV, Rosenberg M, Lindenmaier D, Merkle C, Steen H, Andre F, Schönland SO, Schnabel PA, Schuster T, Röcken C, Giannitsis E, Katus HA, Frey N.

Amyloid. 2014 Sep;21(3):202-10. doi: 10.3109/13506129.2014.940457. Epub 2014 Jul 9.

PMID:
25007036
35.

Noninvasive risk stratification of patients with transthyretin amyloidosis.

Kristen AV, Scherer K, Buss S, aus dem Siepen F, Haufe S, Bauer R, Hinderhofer K, Giannitsis E, Hardt S, Haberkorn U, Katus HA, Steen H.

JACC Cardiovasc Imaging. 2014 May;7(5):502-10. doi: 10.1016/j.jcmg.2014.03.002. Epub 2014 Apr 9.

36.

Skeletal scintigraphy in patients with transthyretin-related amyloidosis.

Kristen AV, Altland K, Katus HA.

Int J Cardiol. 2014 Feb 1;171(2):e16-7. doi: 10.1016/j.ijcard.2013.11.131. Epub 2013 Dec 7. No abstract available.

PMID:
24360159
37.

Modified body mass index and time interval between diagnosis and operation affect survival after liver transplantation for hereditary amyloidosis: a single-center analysis.

Franz C, Hoffmann K, Hinz U, Singer R, Hund E, Gotthardt DN, Ganten T, Kristen AV, Hegenbart U, Schönland S, Hinderhofer K, Büchler MW, Schemmer P.

Clin Transplant. 2013 Jul-Aug;27 Suppl 25:40-8. doi: 10.1111/ctr.12193.

PMID:
23909501
38.

Inhibition of apoptosis by the intrinsic but not the extrinsic apoptotic pathway in myocardial ischemia-reperfusion.

Kristen AV, Ackermann K, Buss S, Lehmann L, Schnabel PA, Haunstetter A, Katus HA, Hardt SE.

Cardiovasc Pathol. 2013 Jul-Aug;22(4):280-6. doi: 10.1016/j.carpath.2013.01.004. Epub 2013 Feb 12.

PMID:
23410819
39.

Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.

Buss SJ, Emami M, Mereles D, Korosoglou G, Kristen AV, Voss A, Schellberg D, Zugck C, Galuschky C, Giannitsis E, Hegenbart U, Ho AD, Katus HA, Schonland SO, Hardt SE.

J Am Coll Cardiol. 2012 Sep 18;60(12):1067-76. doi: 10.1016/j.jacc.2012.04.043. Epub 2012 Aug 8.

40.

Green tea halts progression of cardiac transthyretin amyloidosis: an observational report.

Kristen AV, Lehrke S, Buss S, Mereles D, Steen H, Ehlermann P, Hardt S, Giannitsis E, Schreiner R, Haberkorn U, Schnabel PA, Linke RP, Röcken C, Wanker EE, Dengler TJ, Altland K, Katus HA.

Clin Res Cardiol. 2012 Oct;101(10):805-13. Epub 2012 May 15.

41.

[Amyloidosis of the heart].

Kristen AV, Röcken C.

Pathologe. 2012 May;33(3):236-44. doi: 10.1007/s00292-011-1558-4. Review. German.

PMID:
22318486
42.

Severe left main coronary stenosis in a young female patient, 6 years after mediastinal radiation therapy for non-Hodgkin lymphoma: assessment by coronary angiography and intravascular ultrasound.

Korosoglou G, Kristen AV, Andrassy M, Katus HA, Hardt SE.

Clin Res Cardiol. 2012 Apr;101(4):317-20. doi: 10.1007/s00392-012-0413-9. No abstract available.

PMID:
22286318
43.

[Systemic amyloidoses].

Schönland S, Blank N, Kristen AV, Beimler J, Ganten T, Hegenbart U.

Internist (Berl). 2012 Jan;53(1):51-64. doi: 10.1007/s00108-011-2952-y. German.

PMID:
22033913
44.

Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis.

Kristen AV, Haufe S, Schonland SO, Hegenbart U, Schnabel PA, Röcken C, Hardt S, Lohse P, Ho AD, Haberkorn U, Dengler TJ, Altland K, Katus HA.

Int J Cardiol. 2013 Apr 5;164(2):179-84. doi: 10.1016/j.ijcard.2011.06.123. Epub 2011 Jul 20.

PMID:
21764155
45.

Increased incidence of acute graft rejection on calcineurin inhibitor-free immunosuppression after heart transplantation.

Celik S, Doesch AO, Konstandin MH, Kristen AV, Ammon K, Sack FU, Schnabel P, Katus HA, Dengler TJ.

Transplant Proc. 2011 Jun;43(5):1862-7. doi: 10.1016/j.transproceed.2010.12.059.

PMID:
21693290
46.

Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay.

Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M, Lindenmaier D, Merkle C, Hardt S, Schnabel PA, Röcken C, Schonland SO, Ho AD, Dengler TJ, Katus HA.

Blood. 2010 Oct 7;116(14):2455-61. doi: 10.1182/blood-2010-02-267708. Epub 2010 Jun 25.

47.

[Return to work after heart transplantation].

Kristen AV, Katus HA, Dengler TJ.

Versicherungsmedizin. 2010 Jun 1;62(2):67-72. German.

PMID:
20575476
48.

Acupuncture improves exercise tolerance of patients with heart failure: a placebo-controlled pilot study.

Kristen AV, Schuhmacher B, Strych K, Lossnitzer D, Friederich HC, Hilbel T, Haass M, Katus HA, Schneider A, Streitberger KM, Backs J.

Heart. 2010 Sep;96(17):1396-400. doi: 10.1136/hrt.2009.187930. Epub 2010 Jun 15.

PMID:
20554511
49.

Amyloid in endomyocardial biopsies.

Kieninger B, Eriksson M, Kandolf R, Schnabel PA, Schönland S, Kristen AV, Hegenbart U, Lohse P, Röcken C.

Virchows Arch. 2010 May;456(5):523-32. doi: 10.1007/s00428-010-0909-5. Epub 2010 Apr 8.

PMID:
20376481
50.

Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.

Dietrich S, Schönland SO, Benner A, Bochtler T, Kristen AV, Beimler J, Hund E, Zorn M, Goldschmidt H, Ho AD, Hegenbart U.

Blood. 2010 Jul 29;116(4):522-8. doi: 10.1182/blood-2009-11-253237. Epub 2010 Apr 7.

Supplemental Content

Loading ...
Support Center